Citing potential disclosure requirements from the Food and Drug Administration, lack of insurance coverage and lack of support among clinicians, the founders of stool-donation initiative, OpenBiome, ...

When I took antibiotics for a sinus infection, I began feeling weak and feverish, with diarrhea. I went to the ER and learned I had Clostridioides difficile, an infection in the large intestine. The ...

Clostridium difficile bacteria, computer illustration. C. difficile is a normal inhabitant of the human intestine, but it can become a pathogen when antibiotics disrupt the normal intestinal flora and ...

Harvard researchers make the case for people storing their poop when young, in order to restore their gut microbiomes later in life. Reading time 3 minutes Experts at Harvard and elsewhere are ...

Bethesda, MD (Feb. 21, 2024) — In the first comprehensive evidence-based guideline on the use of fecal microbiota-based therapies for gastrointestinal disease, the American Gastroenterological ...

Costly treatments from Merck & Co and other drugmakers, and a vaccine from Sanofi, are on the horizon. But growing numbers of gastroenterologists are more excited about the use of human stool ...

A trained dog can detect Clostridium difficile in stool samples and in hospital patients, according to a study in the British Medical Journal. Researchers studied a two-year-old beagle trained to ...

Chronic infections with C. diff have reignited interest in fecal transplantation, a procedure that is still not covered by health insurance, according to a report by ABC News. Patients with ...

BOULDER, CO, UNITED STATES, October 8, 2025 /EINPresswire.com/ -- Faex Health, a fast-growing digital health startup, today announced the release of its C. difficile ...

The case could represent the first known instance of cat-to-human transmission of recurrent C. diff, though more research is needed to confirm this risk. Reading time 3 minutes A woman’s newly adopted ...

There are inherent risks in biotech investing. A decade’s worth and often hundreds of millions of dollars in R&D, along with binary risks of failed clinical trials or regulatory approval. Above and ...